相似文献
1
An emerging multidrug-resistant bacteria.一种新出现的多重耐药细菌。
CMAJ. 2017 Sep 5;189(35):E1115. doi: 10.1503/cmaj.170110.
2
Lowering methodological standards for studies of multidrug-resistant bacteria is counterproductive.降低耐多药细菌研究的方法学标准会适得其反。
Clin Microbiol Infect. 2016 Jun;22(6):497-8. doi: 10.1016/j.cmi.2016.03.024. Epub 2016 Apr 2.
3
The challenge of antibiotic resistant bacterial pathogens: the medical need, the market and prospects for new antimicrobial agents.抗生素耐药性细菌病原体的挑战：医疗需求、市场及新型抗菌药物的前景。
Curr Opin Microbiol. 2004 Oct;7(5):435-8. doi: 10.1016/j.mib.2004.08.017.
4
[Multidrug-resistant bacteria require new treatment options].多重耐药细菌需要新的治疗选择。
Med Monatsschr Pharm. 2015 Dec;38(12):517-21.
5
Selecting empiric antibiotic therapy in an era of multi-drug resistance--is the cupboard really bare? Introduction.在多重耐药时代选择经验性抗生素治疗——药橱真的空了吗？引言。
Clin Microbiol Infect. 2008 Dec;14 Suppl 6:1. doi: 10.1111/j.1469-0691.2008.02127.x.
6
[Microbiological approach to antibiotic therapy against multidrug-resistant bacteria].
Nihon Geka Gakkai Zasshi. 2003 Jul;104(7):527-9.
7
Does microbial resistance matter?微生物耐药性重要吗？
Lancet Infect Dis. 2011 Jan;11(1):3-4. doi: 10.1016/S1473-3099(10)70287-5. Epub 2010 Dec 2.
8
Multi-resistant bacteria--recent trends in emerging zoonotic agents.多重耐药菌——新发人畜共患病原体的近期趋势
Berl Munch Tierarztl Wochenschr. 2014 Sep-Oct;127(9-10):337-8.
9
Challenges in the management of serious infections.严重感染管理中的挑战。
Clin Infect Dis. 2006 Jan 15;42 Suppl 2:S63-4. doi: 10.1086/499403.
10
Whither antibacterial drug discovery?抗菌药物研发何去何从？
Drug Discov Today. 2008 Apr;13(7-8):279-80. doi: 10.1016/j.drudis.2008.03.010.
引用本文的文献
1
The Impact of Differences in Surveillance Definitions of Hospital Acquired Urinary Tract Infections (HAUTI).医院获得性尿路感染（HAUTI）监测定义差异的影响
Antibiotics (Basel). 2021 Oct 18;10(10):1262. doi: 10.3390/antibiotics10101262.
2
Health care-associated infections in Canadian hospitals: still a major problem.加拿大医院中的医疗保健相关感染：仍然是一个重大问题。
CMAJ. 2019 Sep 9;191(36):E977-E978. doi: 10.1503/cmaj.190948.
3
Running out of options: Extensively drug-resistant urinary tract infection in an infant.无计可施：一名婴儿的广泛耐药性尿路感染
Paediatr Child Health. 2019 Sep;24(6):371-373. doi: 10.1093/pch/pxz048. Epub 2019 Apr 9.
4
Innovative drugs, chemicals, and enzymes within the animal production chain.动物生产链中的创新药物、化学品和酶。
Vet Res. 2018 Jul 31;49(1):71. doi: 10.1186/s13567-018-0559-1.
本文引用的文献
1
Deaths attributable to carbapenem-resistant Enterobacteriaceae infections.由耐碳青霉烯类肠杆菌科细菌感染导致的死亡病例。
Emerg Infect Dis. 2014 Jul;20(7):1170-5. doi: 10.3201/eid2007.121004.
2
Global spread of Carbapenemase-producing Enterobacteriaceae.产碳青霉烯酶肠杆菌科的全球传播。
Emerg Infect Dis. 2011 Oct;17(10):1791-8. doi: 10.3201/eid1710.110655.
Zotero 插件